Thus, these observations establish that FABP4 inhibitor BMS309403 reduces hypoxia‐induced cardiomyocyte apoptosis through attenuating excessive ER stress, implying that FABP4 inhibition may be of clinical benefit for MI treatment. The gene discussed is FABP4; the disease is myocardial infarction.